In 1969, he joined Edward D. Jones & Co. in Saint Louis and later became a partner. ims conference 2022 myeloma - techmaxservice.com The IMS has reserved rooms for participants at hotels near the meeting venue. Prior to Brera and Colonnade, Dana was head of Financial Institutions Investment Banking and Chief of Staff of Banking and Capital Markets at Deutsche Bank and its predecessor companies. Chairman of the Clinical Advisory BoardZyngenia. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma. By using our websites, you agree to the placement of these cookies. Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma. After completing his graduate studies in Montreal and postdoctoral fellowship at Dana-Farber Cancer Institute/Harvard Cancer Center where he conducted seminal multiple myeloma genomic work, Dr. Auclair then spent a decade in early cancer drug discovery in biotech/pharma, mostly at Bayer where he worked, among others, on overseeing the Bayer-Millennium cancer genomics drug collaboration as well as on Nexavar and Stivarga. For further support with Google Translate, visit Google Translate Help. Ultimately, this meeting serves to engage stakeholders to discuss opportunities and challenges in designing trials applicable to the US patient population. Learn about why and how the tests are done and what the results mean. Mr. McKiernan served as Executive Advisor to Visa, Inc. for two years following the acquisition before founding WSM Capital in 2012. He joined the MMRF after a 25-year career in healthcare informatics for the Life Science Industry where he worked on a wide array of issues ranging from the secondary uses of healthcare data for Life Sciences, health information technology policy, Big Data and analytics and medical affairs. CyberSource provides payment processing and other related services to online businesses. She is chemotherapy certified and is currently in school to obtain her masters degree in nursing education. Michael brings nearly 15 years of strategic consulting and operational experience in the life sciences industry. Donec sed odio dui. Michael earned a B.A. Significant Depth of Response Achieved in Relapsed Multiple Myeloma With Isa-Kd. Susan Marvin, Chair of the Board of The Marvin Companies, was part of the third-generation management team in what is today a fourth-generation family owned and operated company. Earlier, he founded Ridge Computers, designer of the worlds first commercial reduced instruction set computing (RISC) minicomputer. Following graduation from Stanford, he earned his law degree from the University of California at Berkeley (Boalt Hall) in 1986, and was admitted to the California State Bar the same year. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone demonstrated benefit compared with VTd alone in subgroup analyses of patients with high-risk multiple myeloma from the phase III CASSIOPEIA trial. You can help accelerate a cure for each and every myeloma patient. At Peloton, Lori drove business growth with strategy, brand marketing, communications, PR, social/digital media, consumer insights, data analytics, creative services, and community engagement. Cowan: You have to look at a few things, one being their response? She began her career as an inpatient oncology nurse at Yale providing bedside care to patients and then transitioned to Norwalk Hospital where she worked as a chemotherapy infusion nurse. Former board positions include HBA Advisory Board, PhRMA Audit and Finance Subcommittee member, and the T.J. Martell. Upon Randis diagnosis, she conducted an abundance of research and tried to keep an optimistic mindset. LOS ANGELES, June 01, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce the recipients of this years Robert A. Kyle Achievement Award and Brian G.M. Chris holds graduate and post-graduate degrees in Microbiology/Molecular Biology and Protein Biochemistry from Clemson University. Box 414238 First, they are investigating immunologic therapies with a focus on using cutting edge genomic and immunologic assays to map the interaction between myeloma and the immune system in the tumor microenvironment. } In addition, she has been honored with the American Association for Cancer Research Centennial Medal for Distinguished Public Service and the Healthcare Businesswomens Associations Woman of the Year Award. She previously worked in healthcare public relations at Burson-Marsteller and the Chandler Chicco Agency, following a postgraduate internship at the Department of Justice, Antitrust Division. This workshop is intended for but not limited to academia, industry, regulatory agencies, consulting firms, health-technology assessment groups, and patient groups. 36, from Acworth, GA Facon T, Kumar SK, Plesner T, et al. Antitumor Activity Observed With Iberdomide in Heavily Pretreated Myeloma. } She believes its imperative to have the entire team working in tandem. Putting the CAR(T) Before the Horse: Practicalities of T CellActivating Therapies in Multiple Myeloma, Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting (Internal Medicine), Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting (Oncology), Whats My (Next) Line? // document.getElementsByName("captcha_settings")[0].value = JSON.stringify(elems); Chief Operating OfficerSalesforce Essentials. jQuery(".corporate-connections").find("input[name='captcha_settings']").val(JSON.stringify(elems)); Steve led the clinical team that gained approval for Herceptin, a targeted biologic treatment for breast cancer. Do you think its a drug thats better-used upfront or in relapse? Response assessment in multiple myeloma (MM) is guided and classified based on the criteria set out by the International Myeloma Changing practice patterns in autologous transplantation at EBMT centers. Tax ID: 06-1504413 Kathy received her MBA in general management from Harvard Business School and holds an honorary Doctorate from the University of Vermont. Can you share data from the phase 2 GRIFFIN study [NCT02874742] that were presented at the IMS 2022 and your takeaways? Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. From April 2012 through 2014, Meryl was Chief Financial and Administrative Officer of Novartis Pharmaceuticals Corporation in the US, and a member of the Pharmaceutical Executive Committee and Global Finance Leadership Team. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. Mr. McKiernan holds a BS from Boston College and an MBA from the Harvard Business School. She is also the Chief Mission Officer of the MMRF. For further inquiries on leadership and our strategic plan please fill out the below information. WebThe 47th annual Meeting of the Japanese Society of Myeloma / Call for Abstracts [May 20 (Fri)-22 (sun), 2022 Gifu Grand Hotel] Call for Abstracts 1 Submission Period Date: October 22 (Fri.) December 15 (Wed.), 2021 (UTC+9) Abstract Submission is extended to December 22 (Wed.), 2021 (UTC+9) We deeply appreciate for Submitting Abstracts. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. Al Mouna aide chacun tre fier de sa culture particulire. Current Diagnosis: Multiple Myeloma-stable He has also served as an advisor for Harvard Business School's Kraft Precision Medicine program, using his experience with direct-to-consumer teams to help nonprofits accelerate precision medicine efforts via direct-to-patient engagement. Continuing Medical Education (CME/CE) Courses. This meeting She is a member of the Oncology Nursing Society and a nationally Oncology Certified Nurse. Initially Diagnosed: 2014 Previously Karen was the General Counsel and Corporate Secretary of BBDO Worldwide, Inc. where she was responsible for the management of the legal activities of over 150 individual operating units throughout the world. He joined Moore Capital /IMS in 1993 and served as its Director of Trading Operations and then Vice President until IMS split off from Moore in 1995. Please remember that any data you submit or post as user-generated content to the Website become public data. Additional panelists included Larry Anderson, MD, PhD, professor in the Department of Internal Medicine at The University of Texas Southwestern Medical Center in Dallas; Caitlin Costello, MD, associate professor of medicine at the University of California San Diego in California; Andrew J. Cowan, MD, interim clinical director of the Myeloma Service and research associate in the Clinical Research Division at the Fred Hutchinson Cancer Research Center as well as assistant professor in the Division of Medical Oncology at the University of Washington School of Medicine in Seattle; and Rebecca Silbermann, MD, MMS, associate professor of medicine in the Division of Hematology/Medical Oncology at the Oregon Health and Science University School of Medicine in Portland. He also initiated the cancer clinical trials of the anti-angiogenesis agent, Avastin. ONCOLOGY Staff. Epub 2022 Mar 24. Discuss considerations for novel agent combinations and biomarker directed therapy in specific multiple myeloma groups. Evelyn has been living with MM for almost nine years. Jeffery is passionate about raising awareness of MMRF and helping others navigate their way and to find their path. Michael was an Adjunct Professor of Law at his alma mater, The Benjamin Cardozo School of Law of Yeshiva University, for ten years teaching Contract Drafting and Negotiation in the Music Industry. Knowledge is power. Knowledge is power. 52, from Little Silver, NJ The .gov means its official.Federal government websites often end in .gov or .mil. James J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY. He feels that his multiple myeloma journey has made him a better person in that he is more compassionate and understanding. Researchers sought to determine whether belantamab mafodotin would be a viable option for treating patients with relapsed/refractory multiple myeloma. Currently, Dr. Pinizzotto is the named Chair of Obstetrics and Gynecology at Christiana Care Hospital, Newark, Delaware, and is also a trustee of the hospital. RWD Support Isatuximab Triplet as Standard of Care for Multiple Myeloma. if (response == null || response.value.trim() == "") { WebTopics will cover the latest advances in the pathophysiology and therapy of: leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, related malignancies, and exciting developments in cellular therapy. Induction and Consolidation Therapy with Daratumumab Plus KRD Shows Potential in High-Risk Newly Diagnosed Myeloma. Karen E. Andrews is currently SVP and General Counsel for the March of Dimes. Those who achieved MRD negativity did equally well whether they had a transplant or not. Carmen strives to stay positive and maintain a healthy and active lifestyle. FAQs on MM Diagnosis, Prognosis, and Initial Treatment (with Updates), FAQs on Newly Diagnosed Multiple Myeloma (with Updates), FAQs on Multiple Myeloma Following Relapse (with, FAQs on Precursor Conditions (with Updates). We sometimes use Standard Contractual Clauses when transferring Personal Data from a country in the EEA to a country outside the EEA. After completing treatment she was back into a complete response. Triplet therapy, transplantation, and maintenance until progression in myeloma. var elems = JSON.parse(jQuery(".form_mentor").find("input[name='captcha_settings']").val()); This video provides information on laboratory tests that myeloma patients may undergo. Vous devez activer le JavaScript pour la visualiser. If a patient is progressing on a CD38 antibody, Im not going to give another CD38 antibody. elems["ts"] = JSON.stringify(new Date().getTime()); In 2013 he joined a technology startup called Vettery, where he helped to launch the brand and all of its communications while serving as the companys Chief Client Officer & lead brand strategist. Since founding the MMRF in 1998, Kathy has become a widely respected leader in establishing innovative, collaborative research models in the areas of tissue banking, genomics, and clinical trials. He has brought to market countless products and campaigns over nearly 20 years, including high-profile healthcare launches in Vaccines and Womens Health. Before and after his diagnosis, he has continued to participate in his hobbies as a marathon runner, hunter, fisherman, and hiker. WebMultiple MyelomaTypes Plasma cell dyscrasias PCL-like MM Transplant-ineligible MM Chromosomal aberrations Risk MM-related mutations View all Types VIEW ALL The Myeloma 2022 meeting is a high-level discussion forum for research leaders in the field of myeloma, in order to further our understanding of recent advances in myeloma, and to encourage To submit a request, please contact us as set forth in theContact Ussection below. There was a small number of patients who had relapsed from the MRD-SURE cohorts, but those were generally patients who had very high-risk diseases. He manages his lifestyle and nutrition to do what he can to have a full and active life. Initially Diagnosed: 2002 Rodney specializes in transactional law with an emphasis on business formation and planning, mergers and acquisitions, and commercial transactions. Prior to Mount Sinai, she worked as an Oncology nurse at Saint Barnabas Medical Center in New Jersey. Now, if someone responded and progressed, I might think twice about reusing it. Response assessment in multiple myeloma (MM) is guided and classified based on the criteria set out by the International Myeloma Working Group (IMWG) in 2016. Higher levels may indicate better prognosis. Gilmore joined ESPN in August of 1996 as a college football analyst. WebWhy Become a Member. He did his cardiology training at the University for Medicine and Dentistry of New Jersey, his medical training at the University of Pittsburgh and at the Albert Einstein Medical Center in Philadelphia. The other key takeaway is that in this study, patients stayed on their maintenance indefinitely until progression vs in the IFM-2009 study where they stopped after a year and saw inferior overall results when they didnt continue maintenance.5. Presence of specific group of genes can predict low or high risk of early relapse. 59, from Rocky Hill, CT Carfilzomib Plus Lenalidomide/Dexamethasone After Transplant Extends PFS Over Lenalidomide in MM. //